Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality

default

Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality

Authors

Elmowafy, A. Y.,El Maghrabi, H. M.,Eldahshan, K. F.,Refaie, A. F.,Elbasiony, M. A.,Matter, Y. E.,Saleh, H. H.,Shiha, G. E.,Rostaing, L.,Bakr, M. A.

 

Citation
2019
International Urology and Nephrology

51

9
1639-1647
Type
Prospective cohort
Virus targets
Hepatitis C
Interventions
HCV testing and linkage to Care
Linkage to care
Screening and diagnosis
Testing
Setting
National
Target populations
Dialysis patients
Country of development
Egypt
Target location
Egypt
DOI
10.1007/s11255-019-02246-7
Testing strategy
Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test
Laboratory-based antibody test
Laboratory-based PCR/RNA (confirmatory) test
Countries of included studies
Egypt

Health outcomes

Linkage to care

Testing strategy

Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test

Abstract

Background and aims: New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients. Method(s): This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV. Result(s): Mean age was 43.2 +/- 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels. Conclusion(s): The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients. Copyright © 2019, Springer Nature B.V.

Page updated

22 Jan 2021